C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Hepatitis B virus (HBV) encoding the HBV x protein (HBx) is a known causative agent of hepatocellular carcinoma (HCC). Its pathogenic activities in HCC include interference with several signaling pathways associated with cell proliferation and apoptosis. Mutant C-terminal-truncated HBx isoforms are frequently found in human HCC and have been shown to enhance proliferation and invasiveness leading to HCC malignancy. We investigated the molecular mechanism of the reduced doxorubicin cytotoxicity by C-terminal truncated HBx. Cells transfected with C-terminal truncated HBx exhibited reduced cytotoxicity to doxorubicin compared to those transfected with full-length HBx. The doxorubicin resistance of cells expressing C-terminal truncated HBx correlated with upregulation of the ATP binding cassette subfamily B member 1(ABCB1) transporter, resulting in the enhanced efflux of doxorubicin. Inhibiting the activity of ABCB1 and silencing ABCB1 expression by small interfering ribonucleic acid (siRNA) increased the cytotoxicity of doxorubicin. These results indicate that elevated ABCB1 expression induced by C-terminal truncation of HBx was responsible for doxorubicin resistance in HCC. Hence, co-treatment with an ABCB1 inhibitor and an anticancer agent may be effective for the treatment of patients with liver cancer containing the C-terminal truncated HBx.
Abstract
Hepatitis B virus (HBV) encoding the HBV x protein (HBx) is a known causative agent of hepatocellular carcinoma (HCC). Its pathogenic activities in HCC include interference with several signaling pathways associated with cell proliferation and apoptosis. Mutant C-terminal-truncated HBx isoforms are frequently found in human HCC and have been shown to enhance proliferation and invasiveness leading to HCC malignancy. We investigated the molecular mechanism of the reduced doxorubicin cytotoxicity by C-terminal truncated HBx. Cells transfected with C-terminal truncated HBx exhibited reduced cytotoxicity to doxorubicin compared to those transfected with full-length HBx. The doxorubicin resistance of cells expressing C-terminal truncated HBx correlated with upregulation of the ATP binding cassette subfamily B member 1(ABCB1) transporter, resulting in the enhanced efflux of doxorubicin. Inhibiting the activity of ABCB1 and silencing ABCB1 expression by small interfering ribonucleic acid (siRNA) increased the cytotoxicity of doxorubicin. These results indicate that elevated ABCB1 expression induced by C-terminal truncation of HBx was responsible for doxorubicin resistance in HCC. Hence, co-treatment with an ABCB1 inhibitor and an anticancer agent may be effective for the treatment of patients with liver cancer containing the C-terminal truncated HBx.
참고문헌 (27)
- Liu N, "Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells", FEBS Lett, 589, pp.897~903 (2015)
- Arzumanyan A, "Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma", Nat Rev Cancer, 13, pp.123~135 (2013)
- Martin-Vilchez S, "The molecular and pathophysiological implications of hepatitis B X antigen in chronic hepatitis B virus infection", Rev Med Virol, 21, pp.315~329 (2011)
- Ng SA, "Hepatitis B virus X gene and hepatocarcinogenesis", J Gastroenterol, 46, pp.974~990 (2011)
- Kim CM, "HBx gene of hepatitis B virus induces liver cancer in transgenic mice", Nature, 351, pp.317~320 (1991)
- Fan W, "Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B", Virus Genes, 42, pp.162~170 (2011)
- Ali A, "Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma", World J Gastroenterol, 20, pp.10238~10248 (2014)
- Wang J, "Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress : role for AMP kinase", Arterioscler Thromb Vasc Biol, 32, pp.712~720 (2012)
- Sze KM, "C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun", matrix metalloproteinase protein 10 activation in hepatocellular carcinoma, 2013, pp.57, 131~139
- Zhang H, "Identification of a natural mutant of HBV X protein truncated 27 amino acids at the COOH terminal and its effect on liver cell proliferation", Acta Pharmacol Sin, 29, pp.473~480 (2008)
- Zhang X, "A mutant of hepatitis B virus X protein(HBx Delta 127)enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase", Acta Pharmacol Sin, 31, pp.593~600 (2010)
- Ma NF, "COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis", Clin Cancer Res, 14, pp.5061~5068 (2008)
- Quetier I, "C-terminaltruncated hepatitis B virus X protein enhances the development of diethylnitrosamine-induced hepatocellular carcinogenesis", J Gen Virol, 96, pp.614~625 (2015)
- Ng KY, "C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties", Oncotarget, 7, pp.24005~24017 (2016)
- Kachalaki S, "Cancer chemoresistance; biochemical and molecular aspects : a brief overview", Eur J Pharm Sci, 89, pp.20~30 (2016)
- Wu Q, "Multi-drug resistance in cancer chemotherapeutics : mechanisms and lab approaches", Cancer Lett, 347, pp.159~166 (2014)
- Kathawala RJ, "The modulation of ABC transporter-mediated multidrug resistance in cancer : a review of the past decade", Drug Resist Updat, 18, pp.1~17 (2015)
- Januchowski R, "Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin-and vincristine-resistant cell lines", Biomed Pharmacother, 68, pp.111~117 (2014)
- Dean M, "Tumour stem cells and drug resistance", Nat Rev Cancer, 5, pp.275~284 (2005)
- Saad M, "Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer", Nanomedicine (Lond), 3, pp.761~776 (2008)
- Nourbakhsh M, "Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer", Iran J Basic Med Sci, 18, pp.385~392 (2015)
- Jung SY, "C-terminal region of HBx is crucial for mitochondrial DNA damage", Cancer Lett, 331, pp.76~83 (2013)
- Broxterman HJ, "Understanding the causes of multidrug resistance in cancer : a comparison of doxorubicin and sunitinib", Drug Resist Updat, 12, pp.114~126 (2009)
- Llovet JM, "Updated treatment approach to hepatocellular carcinoma", J Gastroenterol, 40, pp.225~235 (2005)
- Yeo W, "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy", Ann Oncol, 15, pp.1661~1666 (2004)
- Gewirtz DA, "A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin", Biochem Pharmacol, 57, pp.727~741 (1999)
- Nitiss KC, "Twisting and ironing : doxorubicin cardiotoxicity by mitochondrial DNA damage", Clin Cancer Res, 20, pp.4737~4739 (2014)